Skip to main content

Table 1 Patients features in relation with chemotherapy schedule

From: Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients

Characteristics of patients

1w-CDDP (N = 114)

3w CDDP (N = 52)

χ2

Entire series N (%)

Gender

 Male

92 (80.7%)

33 (63.5%)

0.0017

125 (75.3%)

 Female

22 (19.3%)

19 (36.5%)

 

41 (24.7%)

Age

 < 70 years

90 (78.9%)

50 (96.2%)

0.005

140 (84.3%)

 > 70 years

24 (21.1%)

2 (3.8%)

 

26 (15.7%)

Baseline KPS

 90–100

60 (52.6%)

49 (94.2%)

0.000

109 (65.7%)

 70–80

52 (45.6%)

3 (5.8%)

 

55 (33.1%)

 60

2 (1.8%)

0 (0%)

 

2 (1.2%)

Tobacco use

 Currently < 10 cigarettes/die

14 (12.3%)

4 (7.7%)

0.000

18 (10.8%)

 Currently 10–20 cigarettes/die

27 (23.7%)

5 (9.6%)

 

32 (19.3%)

 Currently > 20 cigarettes/die

31 (27.2%)

3 (5.8%)

 

34 (20.5%)

 Stopped smoking > 5 years

22 (19.3%)

10 (19.2%)

 

32 (20.5%)

 Never smoking

20 (17.5%)

30 (57.7%)

 

50 (30.1%)

Alcohol

 Currently

75 (65.8%)

15 (28.8%)

0.000

90 (54.2%)

 Past

17 (14.9%)

1 (1.9%)

 

18 (10.8%)

 Never

22 (19.3%)

29 (55.8%)

 

51 (30.7%)

 ND

0 (0%)

7 (13.5%)

 

7 (4.2%)

  1. 1w-CDDP weekly Cisplatin, 3w-CDDP three-weekly Cisplatin, KPS karnofsky performance status, ND not declared